Lawsuits filed in both the US and Canada allege the use of Invokana caused damage to patients’ kidneys but that the makers of Invokana (known generically as canagliflozin) failed to warn patients about that risk.
According to reports, in the US at least 56 separate lawsuits in 11 federal districts have been filed against Janssen Pharmaceuticals, which is owned by Johnson & Johnson. Those lawsuits allege patients were not adequately warned about the risk of kidney damage associated with the use of Invokana. The motion to consolidate is before the Judicial Panel on Multidistrict litigation and requests the MDL be consolidated for pretrial proceedings in New Jersey federal court. Plaintiffs in Pa lawsuits have requested almost 100 lawsuits be consolidated for pretrial proceedings in Pennsylvania. 87 lawsuits are under consideration in that motion, which affects lawsuits, filed in Philadelphia. Johnson & Johnson has filed a motion to dismiss some of the lawsuits, arguing that some filed in Philadelphia have no link to the region and therefore no jurisdiction.
Invokana is a type 2 diabetes medication that has been linked to an increased risk of ketoacidosis and kidney failure. The US FDA and Health Canada have both issued warnings that the risk of diabetic ketoacidosis associated with Invokana is higher than originally believed. Since that time, lawsuits have been filed against Janssen Pharmaceuticals, alleging the company knew or should have known about the risks.
WHAT YOU CAN DO ? Sheller, P.C. is currently accepting Invokana induced injury cases in all 50 states. If you or somebody you know has been diagnosed with a serious complication, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Medical Device Litigation Group or call toll free at(800) 883-2299.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.